JP2019515927A - 感染症の処置のための方法 - Google Patents

感染症の処置のための方法 Download PDF

Info

Publication number
JP2019515927A
JP2019515927A JP2018556356A JP2018556356A JP2019515927A JP 2019515927 A JP2019515927 A JP 2019515927A JP 2018556356 A JP2018556356 A JP 2018556356A JP 2018556356 A JP2018556356 A JP 2018556356A JP 2019515927 A JP2019515927 A JP 2019515927A
Authority
JP
Japan
Prior art keywords
infection
acid
aduremic
subject
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018556356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515927A5 (enExample
Inventor
マーク テッパー，
マーク テッパー，
デレク ダブリュー． ギルロイ，
デレク ダブリュー． ギルロイ，
マドゥール モトワニ，
マドゥール モトワニ，
トレイシー エル． ボンフィールド，
トレイシー エル． ボンフィールド，
Original Assignee
コーバス ファーマシューティカルズ インク．
コーバス ファーマシューティカルズ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーバス ファーマシューティカルズ インク．, コーバス ファーマシューティカルズ インク． filed Critical コーバス ファーマシューティカルズ インク．
Publication of JP2019515927A publication Critical patent/JP2019515927A/ja
Publication of JP2019515927A5 publication Critical patent/JP2019515927A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2018556356A 2016-04-29 2017-04-28 感染症の処置のための方法 Pending JP2019515927A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662329514P 2016-04-29 2016-04-29
US62/329,514 2016-04-29
US201662400503P 2016-09-27 2016-09-27
US62/400,503 2016-09-27
US201762470419P 2017-03-13 2017-03-13
US62/470,419 2017-03-13
PCT/US2017/030236 WO2017190070A1 (en) 2016-04-29 2017-04-28 Methods for the treatment of infection

Publications (2)

Publication Number Publication Date
JP2019515927A true JP2019515927A (ja) 2019-06-13
JP2019515927A5 JP2019515927A5 (enExample) 2020-06-18

Family

ID=60161141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556356A Pending JP2019515927A (ja) 2016-04-29 2017-04-28 感染症の処置のための方法

Country Status (7)

Country Link
US (2) US20190133995A1 (enExample)
EP (1) EP3448377A4 (enExample)
JP (1) JP2019515927A (enExample)
CN (1) CN109715152A (enExample)
AU (1) AU2017258765A1 (enExample)
CA (1) CA3022391A1 (enExample)
WO (1) WO2017190070A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019240212A1 (ja) * 2018-06-14 2019-12-19 株式会社カネカ 薬学的活性成分を含む製剤
WO2022204014A1 (en) * 2021-03-25 2022-09-29 Per Os Biosciences, Llc. Compositions and methods for treating coronavirus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120122917A1 (en) * 1999-03-22 2012-05-17 Craig Rick Travis Method For Treatment Of HIV And Diseases Of Immune Dysregulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
CN1939917A (zh) * 1999-03-22 2007-04-04 免疫力药品有限公司 大麻酯衍生物及其药用
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
WO2004058251A1 (en) * 2002-12-19 2004-07-15 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
DK1903866T3 (en) * 2005-11-07 2016-07-25 Murty Pharmaceuticals Inc Improved release of tetrahydrocannabinol
US9192598B2 (en) * 2008-06-25 2015-11-24 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
JP6689078B2 (ja) * 2013-02-12 2020-04-28 コーバス ファーマシューティカルズ インク． 超高純度なテトラヒドロカンナビノール−１１−酸
US20150328198A1 (en) * 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120122917A1 (en) * 1999-03-22 2012-05-17 Craig Rick Travis Method For Treatment Of HIV And Diseases Of Immune Dysregulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORG MED CHEM, vol. 22, no. 10, JPN6021005755, 2014, pages 2830 - 2843, ISSN: 0004597904 *
PEDIATRIC PULMONOLOGY, vol. 50, no. 41, JPN6021005753, 2015, pages 263 - 194, ISSN: 0004597903 *

Also Published As

Publication number Publication date
CA3022391A1 (en) 2017-11-02
EP3448377A4 (en) 2019-12-25
US20200405687A1 (en) 2020-12-31
EP3448377A1 (en) 2019-03-06
AU2017258765A1 (en) 2018-11-29
US20190133995A1 (en) 2019-05-09
WO2017190070A1 (en) 2017-11-02
CN109715152A (zh) 2019-05-03

Similar Documents

Publication Publication Date Title
US10787502B2 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
US20140275237A1 (en) Beraprost isomer as an agent for the treatment of viral infection
JP6837700B2 (ja) ジピベフリンの使用方法
CN115884759A (zh) 大麻素的用途和制剂
WO2016131100A1 (en) Methods of treating infectious diseases
US20020193369A1 (en) Antifungal compounds and uses therefor
BR112021006132A2 (pt) compostos bifenil sulfonamida para o tratamento de doenças de colágeno tipo iv
US20200405687A1 (en) Methods for the treatment of infection
US20180050034A1 (en) Antifungal treatment of crohn&#39;s disease
CN115397431A (zh) 用于治疗涉及全身过度炎症反应的病症的eclitasertib
CN115515599A (zh) 化合物在真菌感染的治疗中的用途
JP2023548863A (ja) テトラヒドロカンナビノールおよびそれを含む組成物を用いて急性呼吸不全および／または急性呼吸窮迫症候群を治療するための組成物および方法
HK40008280A (en) Methods for the treatment of infection
JP7570499B2 (ja) 肺炎を予防・治療する薬物におけるポリペプチドの応用
EP4403177A1 (en) New combination drug for treating coronavirus infections, pharmaceutical composition and use thereof
CN116600797A (zh) 用于治疗急性呼吸衰竭和/或急性呼吸窘迫综合征的包含四氢大麻酚的组合物
EP1377277B1 (en) Pharmaceutical compositions comprising pravastatin for reducing ldl cholesterol levels
CN117137916A (zh) 盐酸去亚甲基小檗碱在制备预防或治疗银屑病药物的应用
WO2022132786A1 (en) Methods and compositions for treating pericarditis
HK40011695A (en) Norketotifen for treatment of hypercytokinemia and viral infections
Polak beginning of the

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210922